A. Goetz

发表

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

A. Tolcher, C. Takimoto, E. Rowinsky, 2005, Clinical Cancer Research.

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

J. Doroshow, C. Takimoto, J. Grem, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

A. Tolcher, C. Takimoto, A. Patnaik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

C. Takimoto, A. Patnaik, E. Rowinsky, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

D. V. Von Hoff, L. Smetzer, H. Burris, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1

L. Smetzer, H. Burris, D. V. Hoff, 2001 .

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

J. Doroshow, C. Takimoto, J. Grem, 2003, Seminars in oncology.

A Phase I and Pharmacokinetic Study of Squalamine , an Aminosterol Angiogenesis Inhibitor 1

A. Tolcher, C. Takimoto, A. Patnaik, 2003 .

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A. Tolcher, L. Denis, M. Beeram, 2009, Clinical Cancer Research.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

C. Takimoto, D. V. Von Hoff, L. Smetzer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

A. Tolcher, C. Takimoto, M. Saif, 2005, Clinical Cancer Research.

Design and synthesis of novel spirocyclopropyl cyclohexane-1,3-diones and -1,3,5-triones for their incorporation into potent HPPD inhibitors

R. Beaudegnies, A. Mallinger, A. Goetz, 2010 .

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cross-reactivity among edible nuts: double immunodiffusion, crossed immunoelectrophoresis, and human specific igE serologic surveys.

B. Whisman, D. W. Goetz, A. Goetz, 2005, Annals of Allergy, Asthma & Immunology.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

A. Tolcher, C. Geyer, L. Denis, 2003, British Journal of Cancer.

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

A. Tolcher, C. Takimoto, L. Denis, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A P hase I a nd P harmacokinetic S tudy o f P egylated Camptothecin a s a 1 -Hour I nfusion E very 3 W eeks i n P atients With A dvanced S olid M alignancies

A. Tolcher, C. Takimoto, L. Denis, 2003 .

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

M. Hidalgo, G. Weiss, A. Patnaik, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

A. Tolcher, C. Takimoto, A. Patnaik, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer.

C. Takimoto, J. Crowell, R. Bergan, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.